Skip to content
value.today

Evelo Biosciences, Inc.

Formerly Evelo Therapeutics, Inc., VL28, Inc.

Total raised
$132 M
2 rounds on record
Latest round
$82 M
Feb 2018
First round on record
Jan 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Evelo Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2018$82 MNo. 2$50 to $250 million

Evelo Biosciences, Inc.: Raise no. 2, Feb 2018

Investors in this round

15 investors had bought by the notice of Mar 23, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Evelo Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$82 M of $82 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Balkrishan (Simba) B. Gill, Ph.D. · Executive Officer, Director
  • Duncan P. McHale · Executive Officer
  • Jennifer P. Glennon · Executive Officer
  • Mark P. Bodmer, Ph.D. · Executive Officer
  • William P. DeVaul · Executive Officer
  • David P. Perry · Director
  • David R. Epstein · Director
  • Lord Ara P. Darzi · Director
  • Noubar B. Afeyan, Ph.D. · Director
  • Theodose B. Melas-Kyriazi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Balkrishan (Simba) Gill, Ph.D., President and Chief Executive Officer. Newest notice filed Mar 23, 2018 (1 amendment). Read the notice at the SEC.

equitySEC
Jan 2017$50 MNo. 1$50 to $250 million

Evelo Biosciences, Inc.: Raise no. 1, Jan 2017

Investors in this round

11 investors had bought by the notice of Feb 12, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Evelo Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Balkrishan (Simba) A. Gill, Ph.D. · Executive Officer, Director
  • Duncan P. McHale · Executive Officer
  • Jennifer P. Glennon · Executive Officer
  • Mark P. Bodmer, Ph.D. · Executive Officer
  • William P. DeVaul · Executive Officer
  • David A. Berry, M.D., Ph.D. · Director
  • David P. Perry · Director
  • David R. Epstein · Director
  • Lord Ara P. Darzi · Director
  • Noubar B. Afeyan, Ph.D. · Director
  • Theodose A. Melas-Kyriazi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Balkrishan (Simba) Gill, Ph.D., President and Chief Executive Officer. Newest notice filed Feb 12, 2018 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Evelo Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2018).

    SEC Form D · Mar 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Evelo Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship VentureLabs IV, LLCVenture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship VentureLabs V LLCVenture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV-Rx, L.P.Venture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund V General Partner LLCVenture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund V, L.P.Venture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Opportunities Fund I General Partner LLCVenture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Opportunities Fund I, L.P.Venture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship V VentureLabs Rx Fund, L.P.Venture capitalnot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Nutritional Health Disruptive Innovation Fund, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Nutritional Health Side Fund, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Evelo Biosciences, Inc.
NameRoleNamed in
Balkrishan (Simba) B. Gill, Ph.D.Executive officerMar 2018
Duncan P. McHaleExecutive officerMar 2018
Jennifer P. GlennonExecutive officerMar 2018
Mark P. Bodmer, Ph.D.Executive officerMar 2018
William P. DeVaulExecutive officerMar 2018
Balkrishan (Simba) A. Gill, Ph.D.Executive officerFeb 2018
Derek P. AdamsExecutive officerJan 2017
Jackie P. PapkoffExecutive officerJan 2017
Balkrishan (Simba) B. Gill, Ph.D.DirectorMar 2018
David P. PerryDirectorMar 2018
David R. EpsteinDirectorMar 2018
Lord Ara P. DarziDirectorMar 2018
Noubar B. Afeyan, Ph.D.DirectorMar 2018
Theodose B. Melas-KyriaziDirectorMar 2018
Balkrishan (Simba) A. Gill, Ph.D.DirectorFeb 2018
David A. Berry, M.D., Ph.D.DirectorFeb 2018
Theodose A. Melas-KyriaziDirectorFeb 2018
Mark A. PruzanskiDirectorJan 2017